An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a biotech company, has filed two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) to study therapies for obesity. One application is for ASC36, a once-a-month injected peptide that targets the amylin receptor. The other is for ASC36_35 FDC, a once-a-month injection that combines ASC36 with a peptide that activates GLP-1 and GIP receptors. This filing is the paperwork that asks the FDA for permission to begin clinical trials in people in the U.S. The main ingredient here is ASC36, which is described as a peptide amylin receptor agonist. A peptide is a small string of building-block molecules similar to the ones in proteins. An "agonist" means it is designed to copy or boost the action of a natural body signal. Amylin is a hormone that helps control appetite and slows how quickly the stomach empties after a meal, so a drug that activates the amylin receptor aims to reduce hunger and help people eat less. The second product adds a GLP-1/GIP receptor agonist — those are other gut-related hormones that also reduce appetite and improve how the body handles glucose (blood sugar). Combining actions is a strategy companies use to try to get stronger weight-loss effects. Right now the news is about IND submissions, not finished trials. The filing itself means Ascletis wants to start testing these injections in human volunteers in the U.S., but it doesn't tell us results from those trials. From this announcement alone we don’t know how well the drugs work, what dose will be used, or how many people will be in the planned studies. If these compounds have been tested elsewhere or in early-phase studies, that detail wasn't included in the snippet, so it's unclear whether the company already has safety or efficacy data from people in other countries. This matters because long-acting injections that reduce appetite are a big focus in obesity treatment right now. A once-monthly shot would be more convenient than weekly or daily options, and combining different hormonal actions could produce stronger weight loss or better metabolic effects. People living with obesity, doctors who treat metabolic diseases, and investors in biotech will watch these programs because they could expand treatment choices if trials succeed. There are important caveats. IND submission is an early step and does not mean the drugs are proven safe or effective. Peptide drugs that affect appetite and metabolism can cause side effects like nausea, vomiting, or changes in blood sugar, and their long-term safety is still being studied for many newer agents. The FDA will review Ascletis’s data before allowing trials, and subsequent human studies must show the treatments are both safe and beneficial. If you are considering weight-loss treatments, talk with a healthcare provider — don’t assume a newly announced drug is ready for use. Bottom line: Ascletis has asked the FDA to allow human testing of a once-monthly amylin-based injection and a combo version with GLP-1/GIP activity, but this is an early regulatory step and real-world results will depend on future clinical trials.
Source: Yahoo Finance